Podcasts about penn medicine

PART 2I n this episode, we're joined by Dr. Andrew Zhang, and we explore Lumbar Interbody fusion. We discuss indications, relevant anatomy, differences between ALIF, OLIF, XLIF, + much much more.   Dr. Zhang is a board-certified, dual fellowship-trained orthopaedic surgeon specializing in spine surgery. He has a clinical interest in treating complex spinal deformity in adult and pediatric patients, including scoliosis and kyphosis, as well as robotic surgery, minimally invasive techniques, and the latest technology such as endoscopic spine surgery. His patient-centered approach involves empowering patients by educating them on their individual spinal conditions and developing a specific evidence-based treatment plan together with them as if they were his own family members. Dr. Zhang also has a particular interest in teaching residents and medical students and is actively involved in several research studies. He has been published in numerous peer-reviewed scientific journals and textbooks, and he has presented posters and on podiums at several national and international conferences. Dr. Zhang earned dual undergraduate degrees in biology and economics with highest honors from The George Washington University and obtained his medical degree with distinction in research from the same institution. He completed his orthopaedic surgery residency at Louisiana State University. He then completed an advanced spine fellowship at Brown University, followed by additional spine training at Yale University and the Shriners Hospitals for Children in Philadelphia and Shreveport. Dr. Zhang completed a second fellowship in advanced adult and pediatric comprehensive spine surgery at New York-Presbyterian/Columbia University/Cornell University, training with the world's foremost experts in spine surgery. He served as an Assistant Attending and Postdoctoral Clinical Fellow at Columbia University's Vagelos College of Physicians and Surgeons as well as a Clinical Instructor of Orthopedic Surgery in Neurological Surgery at Weill Cornell Medical College. His higher education culminated in graduating with distinction from the Surgical Leadership Program at Harvard University. Prior to joining Penn Medicine, Dr. Zhang was the Chief of Adult and Pediatric Orthopaedic Spine Surgery, as well as an Assistant Professor and the Associate Program Director to the Orthopaedic Surgery Residency at Louisiana State University Health Sciences Center. Education and training Medical School: George Washington University Residency: Montefiore Medical Center Residency: Louisiana State University Hospital Fellowship: Brown University Fellowship: NewYork-Presbyterian/Columbia University Medical Center Fellowship: Harvard University Goal of episode: To develop a baseline knowledge of Lumbar Interbody Fusion In this episode, we cover a wide array of topics including: Lumbar interbody fusion vs posterolateral fusion indications for interbody fusion danger and surgical pearls for ALIF, OLIF, XLIF, PLIF pertininent lumbar spine surgical anatomy 

In this episode, we're joined by Dr. Andrew Zhang, and we explore Lumbar Interbody fusion. We discuss indications, relevant anatomy, differences between ALIF, OLIF, XLIF, + much much more.   Dr. Zhang is a board-certified, dual fellowship-trained orthopaedic surgeon specializing in spine surgery. He has a clinical interest in treating complex spinal deformity in adult and pediatric patients, including scoliosis and kyphosis, as well as robotic surgery, minimally invasive techniques, and the latest technology such as endoscopic spine surgery. His patient-centered approach involves empowering patients by educating them on their individual spinal conditions and developing a specific evidence-based treatment plan together with them as if they were his own family members. Dr. Zhang also has a particular interest in teaching residents and medical students and is actively involved in several research studies. He has been published in numerous peer-reviewed scientific journals and textbooks, and he has presented posters and on podiums at several national and international conferences. Dr. Zhang earned dual undergraduate degrees in biology and economics with highest honors from The George Washington University and obtained his medical degree with distinction in research from the same institution. He completed his orthopaedic surgery residency at Louisiana State University. He then completed an advanced spine fellowship at Brown University, followed by additional spine training at Yale University and the Shriners Hospitals for Children in Philadelphia and Shreveport. Dr. Zhang completed a second fellowship in advanced adult and pediatric comprehensive spine surgery at New York-Presbyterian/Columbia University/Cornell University, training with the world's foremost experts in spine surgery. He served as an Assistant Attending and Postdoctoral Clinical Fellow at Columbia University's Vagelos College of Physicians and Surgeons as well as a Clinical Instructor of Orthopedic Surgery in Neurological Surgery at Weill Cornell Medical College. His higher education culminated in graduating with distinction from the Surgical Leadership Program at Harvard University. Prior to joining Penn Medicine, Dr. Zhang was the Chief of Adult and Pediatric Orthopaedic Spine Surgery, as well as an Assistant Professor and the Associate Program Director to the Orthopaedic Surgery Residency at Louisiana State University Health Sciences Center. Education and training Medical School: George Washington University Residency: Montefiore Medical Center Residency: Louisiana State University Hospital Fellowship: Brown University Fellowship: NewYork-Presbyterian/Columbia University Medical Center Fellowship: Harvard University Goal of episode: To develop a baseline knowledge of Lumbar Interbody Fusion In this episode, we cover a wide array of topics including: Lumbar interbody fusion vs posterolateral fusion indications for interbody fusion danger and surgical pearls for ALIF, OLIF, XLIF, PLIF pertininent lumbar spine surgical anatomy 

This episode provides a new perspective on how modern surgical practice has been shaped by military surgical history and how history can provide surgeons with a deepened appreciation for the events that have transformed patient care. Colonel (Ret.) Jeremy W. Cannon, MD, SM, FACS, leads the discussion that includes a medical student, junior faculty member, and senior surgeon/historian. Dr. Cannon's guests are Gordon L. Telford, MD, FACS, Justin Barr, MD, PhD, and Karina Hiroshige.   HOST Colonel (Ret.) Jeremy W. Cannon, MD, SM, FACS, USAF Reserve, MC, trauma surgeon at Penn Medicine in Philadelphia and Past President of the Excelsior Surgical Society   GUESTS Gordon L. Telford, MD, FACS, retired general surgeon from the Medical College of Wisconsin, in Milwaukee   Justin Barr, MD, PhD, transplant and hepatobiliary surgeon at the Ochsner Clinic in New Orleans, LA   Karina Hiroshige, MD/MBA Candidate at the University of Rochester School of Medicine & Dentistry, NY, and Research Fellow in Trauma, Surgical Critical Care & Emergency Surgery at the University of Pennsylvania, Philadelphia   Talk about the podcast on social media using the hashtag #HouseofSurgery    

When David Fajgenbaum nearly died of Castleman disease for the fifth time, he decided to take fate into his own hands. Using his medical training, he searched for an existing drug that might save his life—and found one. Now his organization, Every Cure, is scaling the same approach to uncover hidden treatments for other diseases with no known cure. David and Claudia discussed: How Every Cure is using AI to test 75 million possible disease-drug combinations The perverse incentives that keep generic drug repurposing in the shadowsWhy the hardest part of innovation isn't discovery, it's getting proven treatments into clinical practiceRepurposing existing drugs makes so much sense. But as David points out, there's no market for it:“Once a drug is generic.. the price is going to plummet… And even if you were to double the sales of your drug because you found a new disease area, now you've gone from 1% to 2% of what you got before… So there's no incentive whatsoever for our system to find a new use for a generic drug. Zero incentive.”Relevant LinksLearn more about Every CureRead David's book Chasing My Cure: A Doctor's Race to Turn Hope Into ActionWatch David's TEDTalk Listen to David's Podcast interview with Adam GrantGet info on the Dada2 FoundationWatch a video on Matt Might's story About Our GuestDavid Fajgenbaum, MD, MBA, MSc, is co-Founder & President of Every Cure and a physician-scientist at the University of Pennsylvania, where he is one of the youngest faculty members ever to receive tenure at Penn Medicine. He is also the national bestselling author of Chasing My Cure: A Doctor's Race to Turn Hope Into Action, which is being adapted into a film by Forrest Gump producer Wendy Finerman. During medical school, Fajgenbaum discovered a treatment that saved his own life and founded the Castleman Disease Collaborative Network. He has advanced 13 more repurposed treatments for cancers and rare diseases and co-founded Every Cure to unlock more hidden cures from existing medicines which has received over $100M from ARPA-H and TED's Audacious Project. He also serves on the Board of Directors for the Reagan-Udall Foundation for the FDA. One of the youngest recipients of multiple top NIH and FDA grants, Fajgenbaum has authored over 100 scientific papers in leading journals, including The New England Journal of...

In this episode, John P. Donohue, Vice President of Data and Technology Solutions at Penn Medicine, shares insights on navigating healthcare complexity, implementing AI and extended reality tools, and balancing intentional technology adoption with emerging opportunities. He also discusses the importance of lifelong learning, mentorship, and servant leadership in driving organizational success.

Listen to this powerful interview with Dr. David Fajgenbaum who has an incredible new memoir, "Chasing My Cure: A Doctor's Race to Turn Hope into Action". David's story is truly unique; it's a tale of learning to live, while dying: a universally relatable story about getting up and fighting back after life knocks you down.A former Georgetown quarterback nicknamed "The Beast," David Fajgenbaum was also a force in medical school, where he was known for his unmatched mental stamina. But things changed dramatically when he began suffering from inexplicable fatigue. In a matter of weeks, his organs were failing and he was read his last rites. Doctors were baffled over a condition they had yet to even diagnose; floating in and out of consciousness, Fajgenbaum prayed for the equivalent of a game day overtime: a second chance.Miraculously, Fajgenbaum survived, but only to endure repeated near-death relapses from what would eventually be identified as a form of Castleman disease—an extremely deadly and rare condition that acts like a cross between cancer and an autoimmune disorder. When he relapsed on the only drug in development and realized that the medical community was unlikely to make progress in time to save his life, Fajgenbaum turned his desperate hope for a cure into concrete action: between hospitalizations he studied his own charts and tested his own blood samples, looking for clues that could unlock a new treatment. With the help of family, friends and mentors, he also reached out to other Castleman disease patients and physicians, and eventually came up with an ambitious plan to crowdsource the most promising research questions and recruit world- class researchers to tackle them; instead of waiting for the scientific stars to align, he proposed to align them himself.More than five years later and now married to his college sweetheart, his hard work has paid off: a treatment that he identified has induced a tentative remission and his novel approach to collaborative scientific inquiry has become a blueprint for advancing rare disease research. His incredible story demonstrates the potency of hope, and what can happen when forces of determination, love, family, faith and serendipity collide.David Fajgenbaum, MD, MBA, MSc is one of the youngest individuals to be appointed to the faculty at Penn Medicine. Co- founder and executive director of the Castleman Disease Collaborative Network (CDCN) and an NIH-funded physician- scientist, he has dedicated his life to discovering new treatments and cures for deadly disorders like Castleman disease, which he was diagnosed with during medical school. He is in the top 1 percent youngest grant awardees of an R01, one of the most competitive and sought-after grants in all of biomedical research. Dr. Fajgenbaum has been recognized on the Forbes 30 Under 30 healthcare list, as a top healthcare leader by Becker's Hospital Review, and one of the youngest people ever elected as a Fellow of the College of Physicians of Philadelphia, the nation's oldest medical society. He was one of three recipients – including Vice President Joe Biden – of a 2016 Atlas Award from the World Affairs Council of Philadelphia. Order "Chasing My Cure" at bookstores nationwide or at http://www.chasingmycure.com/Business Leadership Series Intro and Outro music provided by Just Off Turner: https://music.apple.com/za/album/the-long-walk-back/268386576

En EEUU, la hija del exmandatario Joe Biden que salió de la presidencia humillado por Donald Trump debido a su sistucaión de salud, compartió en redes socailes que su padre de 82 años, terminó su tratamiento de radioterapia contra el cáncer de próstata. En un gesto simbólico, tocó la campana en el centro Penn Medicine de Filadelfia, una tradición entre pacientes oncológicos que superan esa etapa.

Beau Wangtrakuldee is the founder and CEO of AmorSui, a science-backed medical supply brand bringing innovation, safety, and sustainability to the $58B PPE industry. A former scientist turned entrepreneur, Beau is reimagining protective apparel with clean chemistry, circular materials, and design that finally puts the user first.After a lab accident exposed the flaws in traditional PPE, Beau built AmorSui to bridge the gap between safety, comfort, and sustainability: offering PFAS-free, recyclable, and biobased alternatives trusted by global brands like Thermo Fisher Scientific and Benco Dental.Whether you're building a mission-driven ecommerce brand or rethinking your product's lifecycle, Beau shares a masterclass in turning real-world problems into scalable innovation, proving that circular design and commercial growth can coexist.In This Conversation We Discuss:[00:30] Intro[01:01] Building comfort and safety into every product[01:46] Creating a business from personal experience[04:37] Designing products people actually reuse[06:10] Validating ideas through real user stories[08:12] Raising capital before manufacturing begins[08:47] Allocating funds beyond first production run[09:45] Navigating minimum order quantity realities[10:32] Launching pre-sales with finished prototypes[11:04] Stay updated with new episodes[11:14] Balancing safety standards with speed to market[12:37] Episode Sponsors: Electric Eye & Heatmap[15:18] Marketing through word-of-mouth momentum[17:01] Refining targeting through early experiments[19:00] Discovering growth through customer feedback[21:34] Testing demand before building logistics[23:17] Learning quickly by shipping imperfect products[24:09] Focusing every decision on the end userResources:Subscribe to Honest Ecommerce on YoutubeModern PPE brand that protects people and the planet amorsui.com/Follow Beau Wangtrakuldee linkedin.com/in/beauwangtrakuldeeSchedule an intro call with one of our experts electriceye.io/connectClear, real-time data built for ecommerce optimization heatmap.com/honestIf you're enjoying the show, we'd love it if you left Honest Ecommerce a review on Apple Podcasts. It makes a huge impact on the success of the podcast, and we love reading every one of your reviews!

When baby KJ was diagnosed with a rare metabolic disorder, the team at Children's Hospital of Philadelphia (CHOP) had a unique treatment option for him: a personalized gene editing therapy developed in collaboration with Penn Medicine. On this episode, Madeline speaks to CHOP geneticist Dr. Rebecca Ahrens-Nicklas, who describes how KJ's first-of-its-kind treatment was developed – and what this amazing breakthrough means for other patients. 

JCO PO author Dr. Bryson Katona at the University of Pennsylvania Perelman School of Medicine shares insights into his article, “Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium” Host Dr. Rafeh Naqash and Dr. Katona discuss how, given differing guidelines as well as lack of detail about how PC surveillance should be performed, approaches to PC surveillance across centers often differs. TRANSCRIPT Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, I am thrilled to be joined by Dr. Bryson Katona, Director of the Gastrointestinal Cancer Genetics Program and Director of the Lynch Syndrome Program at the Penn Medicine's Abramson Cancer Center, and also lead author of the JCO PO article entitled "Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection or PRECEDE Consortium." Bryson, thanks for joining us again. Dr. Bryson Katona: Well, thank you so much for having me. I appreciate the opportunity. Dr. Rafeh Naqash: It is exciting to see that this work will be presented concurrently with the upcoming CGA meeting. Dr. Bryson Katona: Yes, it has been a fantastic partnership between JCO PO and the CGA-IGC and their annual meeting. And for those who may not be familiar, the CGA-IGC is the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. It is basically a professional organization dedicated to individuals who have hereditary GI cancer risk and focusing on providing education, promoting research, and really bringing together providers in this space from not just throughout the US but from across the globe as well. Dr. Rafeh Naqash: That is exciting to hear the kind of work you guys are doing. These are definitely interesting, exciting things. Now, going to what you have published, it is an area that is very evolving in the space of cancer screening, cancer surveillance, especially for a very aggressive cancer such as pancreatic cancer. Could you tell us currently, what are the general consensus? I know there are a lot of differences between different guidelines or societies, but what are the some of the commonalities if we were to start there first for pancreas cancer screening? If you are not a GI oncologist, you may not be aware that there is something with regards to pancreas cancer screening. Could you give us an overview and a background on that? Dr. Bryson Katona: Yeah, I think that pancreatic cancer screening really is one of the most controversial areas of all cancer screening. Part of that controversy is just because all the guidelines, the many different guidelines that are out there, do not always match up with one another, which I think leads to a lot of confusion, not just for providers but for patients who are trying to go through this, and then also the insurance companies in trying to get these screening tests covered. You know, when we think about who is eligible for pancreatic cancer screening, you know, it is important that these are not average-risk individuals. So really, we are only offering screening to high-risk individuals. And those can include people that have a strong family history of pancreatic cancer without a germline genetic susceptibility that has been identified. And those individuals we refer to as having familial pancreatic cancer. And the other big cohort is those individuals that carry hereditary pancreatic cancer predisposition. These are due to cancer risk mutations in many different genes, including many of the breast cancer risk genes like BRCA1 and BRCA2, as well as ATM and PALB2, but then other genes such as the Lynch syndrome genes, and then some of the higher risk genes such as those leading to Peutz-Jeghers syndrome as well as FAM, which is due to CDKN2A mutations. Dr. Rafeh Naqash: Thank you for that. Again, another practical question, and this may or may not be exactly related to your specific topic here, but perhaps to some extent there might be an overlap. If I get a patient from a colleague, and I see people in the early-phase clinical trial setting, so many different tumors for novel drugs, and I find an individual with, let us say, lung cancer who has a pathogenic BRCA2, which is somatic, should I be worried about pancreas cancer screening in that individual? Or have we not met that threshold yet in that circumstance? Dr. Bryson Katona: A lot of times these variants or these genes that are associated with pancreatic cancer risk get picked up on the somatic tumor profiles. Now, you know, whether or not those are truly germline variants typically requires the next step of referring the patient for germline genetic testing. So you know, I would not screen or make any kind of screening choices based on a somatic variant alone, but nowadays germline testing is so easy, so efficient, and relatively cheap that it is easy enough to confirm whether or not these somatic hits are in fact just somatic or may confer some germline risk in addition. Dr. Rafeh Naqash: So from what I understand from what you have said, there is debate about it, but it is something that should be done or is important enough that you need to figure out a path moving forward. Was that one of the reasons why you performed this project through this very interesting consortium called the PRECEDE Consortium? Dr. Bryson Katona: Yeah, that was one of our main reasons for doing this. And for those who do not know about the PRECEDE Consortium, this is a very large international, multi-institutional organization really focused on reducing death and improving survival from pancreatic cancer, primarily through increased and more effective use of screening and early detection strategies. This is an international consortium. There are over 50 sites now with nearly 10,000 patients who are enrolled in the consortium. So it really is at this point the largest prospective study of individuals who are at high risk for pancreatic cancer who are undergoing screening. And you know, I think amongst all of us in the consortium, just amongst discussions between colleagues and then, you know, often times when I see patients that are transferring their care to Penn who maybe had their screening done in another center before, what we were realizing is that, you know, although we all do a lot of screening, it seems that people are doing it slightly differently. And it does not seem that there is a real consensus approach across all centers about how pancreatic cancer screening should really be done. And it is one thing if you are thinking comparing, okay, well, maybe in the US we do it differently than, you know, in Europe or in other locations, but even among centers within the United States, we were still seeing very large differences in how pancreatic cancer screening in high-risk individuals were done. And so that led us to really pursue this survey of pancreatic cancer screening practices across the PRECEDE Consortium. So for this survey, we actually have 57 centers who the survey was sent out to. As you know, surveys are oftentimes very difficult to get good response rates back on, but we were fortunate to have 54 of the 57, or 95% of the centers, actually get back to us about their screening practices for this particular project. Dr. Rafeh Naqash: That is good to know. I hope you did not have to use any kind of gift cards for people to respond to the survey. But nevertheless, you got the information that you needed. Could you tell us what are some of the common denominators that you did identify and some of the differences that you identified? From your perspective, it sounds like there is no established consensus guidelines. There are different societies that have different perspectives on it. So I am sure some of what you found will probably have implications in maybe creating some guidelines. Is that a fair statement? Dr. Bryson Katona: Definitely a fair statement, and we found some very interesting results. I think one important result is really just the heterogeneity in the consortium. And so even before we got into pancreatic cancer screening practices, we also, we were asking consortium sites, “At your particular site, who is the individual that is leading these in-depth discussions about pancreatic cancer screening?” And while about 50% of the sites had a gastroenterologist leading it, about a quarter of the sites had a medical oncologist, a quarter had a surgeon leading these discussions as well. And we also found heterogeneity in who is the physician or the provider actually ordering these screening tests, again, with multiple different specialties across the different sites. But really one of the main areas that we wanted to hone in and focus on was how the different pancreatic cancer screening guidelines were actually utilized in each of the particular centers. The biggest controversial area in the field is for the gene mutation carriers, whether or not we should be requiring that a family history of pancreatic cancer be present in order for those individuals to qualify for pancreatic cancer screening. And the reason that is so controversial, let us take an example of BRCA1 and BRCA2 carriers. Currently, if you look through the guidelines, NCCN and the ASGE guidelines recommend that really all BRCA2 carriers undergo pancreatic cancer screening regardless of whether or not there is a family history, starting at age 50. However, other guidelines such as the AGA guidelines, or the AGA Clinical Practice Statement, as well as guidelines from the CAPS consortium, do recommend that a family history of pancreatic cancer be present in order to qualify for screening. But then we have different things for other genes. So for BRCA1 carriers, in fact, it is the ASGE guidelines that recommend all BRCA1 and 2 carriers undergo screening, whereas NCCN and the other guidelines that are out there do not recommend those individuals undergo screening. Again, this huge heterogeneity in guidelines is quite striking. And so when we assessed all the sites in the PRECEDE Consortium, we found some really interesting results with respect to these particular genes. For BRCA2 carriers specifically, we found that about half of the sites required a family history for recommending pancreatic cancer screening, but about half of the sites would offer it to all BRCA2 carriers regardless of if there was a family history of pancreatic cancer screening. Rates for BRCA1, PALB2, and ATM carriers were a little bit lower, where about a third of sites would offer screening really regardless of whether or not there is a family history of pancreatic cancer. And for Lynch syndrome, those rates were very, very low, with only about 13% of sites offering screening to Lynch patients in the absence of a family history. But I think, you know, we are all in the same consortium, but there is still just a lot of heterogeneity in how our own individual practices are run. Dr. Rafeh Naqash: Definitely different thoughts, different practices. But from what you saw, did it matter as far as outcomes are concerned whether it was a gastroenterologist doing the screening, or it was a medical oncologist, or a geneticist? Or is it a combination of all of these that actually makes the most difference? Dr. Bryson Katona: So I think we do need to get some more information about specialty-specific screening preferences. We just had one response per site in this particular survey, and so I think we are going to need a larger sample size in order to get that data. But I think that is certainly possible that, you know, certain subspecialties may prefer, you know, screening more aggressively or not including family history. That is definitely a question that we will be asking in future studies. Dr. Rafeh Naqash: Definitely more gift cards that will be needed as well. Moving on to another aspect of the implications for early detection, from a breast cancer, colon cancer standpoint, there is health economics research that shows it saves cost in the bigger picture. Has there been anything for pancreas cancer where early detection, early identification, early treatment actually ends up saving a lot more versus detecting metastatic pancreas cancer later? Dr. Bryson Katona: It is a great question. And of course, for any screening modality, you know, we would ultimately want it to be a cost-effective measure. In pancreas cancer screening, the jury is still a little bit out about whether or not pancreas cancer screening is truly cost-effective or not. There have been several different studies that have assessed this. And I think in general, the thought is that it is a cost-effective endeavor. But I think most of these cost-effectiveness estimates are actually related to what is the risk of pancreatic cancer in the population you are studying. And so when you have very, very high-risk individuals that have over a 10% lifetime risk of pancreatic cancer, it is almost a certainty that pancreatic cancer screening is going to be cost-effective. However, you know, if you have, say for example, BRCA1 carriers where lifetime risk of pancreatic cancer may be less than 5%, likely around like 3%, those individuals, I think it is going to be a tougher sell to say that it is cost-effective. But as we get more data on pancreatic cancer screening, that will be a very important question to ask. And you know, when you mentioned how does it save money, our goal at least in pancreatic cancer screening is to really downstage pancreatic cancer at the time of diagnosis and allow someone to undergo, you know, ideally a curative-intent surgery. There is data out there showing that we can downstage the cancers, that survival after the time of diagnosis is substantially increased after detection in a pancreatic cancer screening program. But again, these are studies that are based on fairly small numbers of converters. And so I think we need more data in that space as well, which is one of the main questions that the PRECEDE Consortium is trying to answer with all of our prospective data. Dr. Rafeh Naqash: Excellent. Well, I hope we see more interesting, exciting work from the PRECEDE Consortium at meetings as well as as a publication in JCO PO. I would like to shift gears briefly for a minute or two, Bryson, to you as an individual, your career. How have you evolved over the last 5, 7 years? How did you end up doing cancer genetics? What were some of the lessons that you learned along the way and some of those that you would want to share with our listeners, especially trainees and early-career faculty? Dr. Bryson Katona: Just to give you and others listening a little bit of background, but I am a physician-scientist, gastroenterologist, but a physician-scientist. And so my clinical practice is exclusively focused on individuals with hereditary GI cancer risk. I run a basic science lab where we do a lot of studies in organoids and mouse models of these hereditary GI cancer risk syndromes. And then I also have a clinical research group where we do early-phase clinical trials and screening and early detection trials, again in these same individuals with hereditary GI cancer risk. I think probably the most important thing that kind of allowed me to get to this stage in my career where I am trying to, you know, essentially try to juggle all three of these balls at the same time is that I absolutely love what I do. And I am so incredibly interested in what I do. And I think for young individuals that are coming through the pipeline and going through training, you know, I mean, finding a specialty and a clinical niche where you truly just enjoy the work and you enjoy the patients and you enjoy your colleagues is by far the most important thing. I ended up getting into the hereditary GI cancer space because a lot of my work earlier on in my career during my PhD and then in my postdoc work in the lab really focused on colorectal cancer. And I thought that focusing on cancer genetics could allow me to really continue to think from the molecular side of things while simultaneously being a gastroenterologist and taking care of patients with hereditary cancer risk. Dr. Rafeh Naqash: Well, thank you so much for giving us a sneak peek of your journey and insights on what perhaps works best, especially when you love what you do. I think that is one of the most important reasons a work tries to keep you going and keep you interested, keep you passionate. So thank you again. Thank you for listening to JCO Precision Oncology Conversations. Do not forget to give us a rating or a review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

For decades, clinical trial recruitment has been the biggest challenge in the industry. Christine Senn, senior vice president of Site-Sponsor Innovation at Advarra, offers insights into why the struggle continues, such as delays in getting regulations updated after a quarter of a century, and how to overcome the deadlock in clinical trial recruitment that is tied to current obsolete marketing guidelines. Also, host Deborah Borfitz shares the latest on beta blockers, low dose aspirin lowering the risk of recurring colorectal cancer, repurposing drugs for breast cancer relapse prevention, remote participation research on why athletes and military members face higher ALS risk, and the first agentic AI platform for life sciences from Medable. Show Notes News Roundup Rethinking beta blockers Press release on the Mount Sinai website Subgroup analysis study in the European Heart Journal Aspirin lowers risk of colorectal cancer recurrence Study in The New England Journal of Medicine  CLEVER study to prevent breast cancer relapse Study in Nature Medicine News release on Penn Medicine website   Champion Insights ALS initiative News release on Answer ALS website Medable's Agent Studio Press release on the Medable website Disseminating research findings Systematic review in PLOS Medicine  Guest Christine Senn, Ph.D., senior vice president of site-sponsor innovation at Advarra The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.

In this episode, Michele Volpe, Chief Operating Officer of the University of Pennsylvania Health System, shares how Penn Medicine is balancing operational efficiency, workforce strategy, and regional expansion. She highlights the organization's efforts to bring advanced therapies closer to communities while reinvesting in people and facilities to build a stronger future.

Are you owning your voice or still shrinking in rooms where you belong?In this episode of Career Gems for the Journey podcast, Leah C. Murphy sits down with Dawana Holmes, an accomplished leadership strategist and executive coach, for a conversation that speaks directly to anyone who's ever second-guessed their power.Dawana opens up about what it truly means to take up space as a woman, especially as a woman of color, in corporate and leadership settings. From dismantling the “be grateful to be here” mindset to challenging the ways we're taught to dim our light, this episode is a call to reclaim your brilliance without apology.

Few topics matter more to parents than the medical well-being of their children. We sit down with Brad Myer, MD, to learn from his decades of experience as a leading local pediatrician. The founder of All Star Pediatrics, in Exton, Pennsylvania, Brad spent almost two decades growing an independent medical group. In our conversation, Brad talks us through the buying the practice from Penn Medicine and growing it to serve thousands of families, while navigating the world of health insurance, and recruiting and retaining a top team around him. Now with the management of the practice behind him, Brad walks us through how he gives back to his local community through board leadership and volunteerism with a number of local organizations.OUR PARTNERSouthern Chester County Chamber of CommerceLINKSAll Star PediatricsWebsite: allstarpediatrics.comBrad Dyer on LinkedInAdditional OrganizationsChester County Food BankBetter Days AheadWest Chester Food CupboardPhoenixville Area Community Services (PACS)Community Volunteers in Medicine (CVIM)Phoenixville Free Clinic (Phoenixville Free Medical Clinic)Area HospitalsChildren's Hospital of Philadelphia (CHOP)Nemours Children's HealthPenn MedicineRelated EpisodesFighting Food Insecurity Locally with Andrea YoundtTranscriptThe full transcript will be posted on our website as soon as it is available.

How can genetic insights change the way we treat cancer?In this episode of the PQI Podcast, Dr. Soni Tuteja, Director of Pharmacogenomics at Penn Medicine, shares how her team put pharmacogenomic testing into practice — and the impact it's had on patients. She highlights findings from her Journal of Clinical Oncology article on DPYD and UGT1A1 testing in GI cancers, showing how pre-treatment testing helped reduce toxicities, guide dose adjustments, and support safer therapy.Listeners will also hear about:Practical strategies to expand and sustain pharmacogenetic testing in real-world settingsHow pharmacists can lead patient counseling and program implementationThe role of NCODA's Positive Quality Interventions (PQIs), like DPYD testing before fluoropyrimidine treatment, in helping teams deliver safer, more personalized care

For more than two decades, advanced practice providers at the Penn Surveillance Clinic have monitored and counseled patients with bicuspid aortic valve (BAV) disease. A congenital disorder, BAV is associated with the connective tissue syndromes and in these and other affected populations is a leading cause of irreversible aortic root dilation, aneurysm, rupture, and dissection. Affiliated with the Center for Bicuspid Aortic Valve Diseases at Penn Medicine, the APP-led Surveillance Clinic follows patients as they progress from dilation to aneurysm to monitor the size of their aortic diameter via imaging, adjust treatment plans, and, when needed, prepare patients for surgery and recovery.

Earlier this year, baby KJ became the first patient in the world to receive a personalized gene editing therapy, which was developed by a team at Children's Hospital of Philadelphia (CHOP) and Penn Medicine. In June, KJ went home after spending more than 300 days at CHOP. On this episode of Breaking Through, Madeline speaks to KJ's parents, Kyle and Nicole, about the treatment that changed KJ's life – and how he's doing today.

Validation of AHA PREVENT in healthcare populations| JACC Deep Dive In this JACC Deep Dive, JACC Editor in Chief Harlan M. Krumholz, MD, SM, explores a study led by Dr. Pradeep Natarajan that evaluates how well the new AHA PREVENT risk equations predict cardiovascular events across four major U.S. health systems. The study found wide variation in performance—PREVENT was well-calibrated at Penn Medicine but significantly underestimated risk at Mass General Brigham and Vanderbilt, particularly among women and minority groups. Reviewers praised the importance and rigor of the work but raised key questions about model calibration, fairness in outcome comparisons, and whether truly "plug-and-play" risk tools are realistic across diverse healthcare environments.

Join host Geoffrey Rubin, MD, MBA, FACR, for a candid and wide-ranging conversation with Mitchell D. Schnall, MD, PhD, FACR—Professor of Radiology and Senior Vice President for Data and Technology Solutions at Penn Medicine. A highly accomplished radiology researcher and leader, Dr. Schnall served for 12 years as Vice Chair for Research in the Department of Radiology at the University of Pennsylvania, followed by another 12 years as Chair. His national leadership includes serving as Chair of ACRIN and the ACR Commission on Research, as well as President of the Academy for Radiology and Biomedical Imaging Research. His research contributions have earned him election to the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine. In this episode, Dr. Schnall reflects on his journey—from a curious kid with a ham radio license and an Ivy League gymnast to a nationally recognized leader in academic radiology. He shares how his background in physics and engineering shaped his hands-on approach to problem-solving, innovation, and leadership—including his early work developing MRI coils and his unexpected path into breast imaging research. Dr. Schnall also discusses lessons from his time leading Penn Radiology, his philosophy on team building and faculty development, and why embracing discomfort, trusting others, and taking smart risks are essential traits for effective leadership. With humility, clarity, and a touch of humor, Dr. Schnall offers valuable insights into the realities of leading in academic medicine, the importance of intellectual generosity, and the power of staying curious throughout one's career. Don't miss this thoughtful conversation with a leader who continues to shape the future of radiology—while never losing sight of the joy in figuring things out. Behind the Mic! Dr. Schnall and his wife have been married for 37 years. Together, they have a 32-year-old daughter, a 29-year-old son, and an 11-month-old granddaughter! When he's not working, Dr. Schnall loves to take things apart and put them back together. He is a serious “DIYer”, having renovated his own kitchen and multiple bathrooms at his home. He also enjoys riding his bicycle and eating spicey hot peppers!

The United States Supreme Court upheld a Tennessee law banning some gender-affirming care for minors, and 26 other states have passed similar laws. Here in Philadelphia, Penn Medicine recently announced that they will no longer provide gender-affirming surgeries for people under 19. To get a better understanding of why some people want or need these procedures, Racquel Williams listens to personal experiences from Jasper Liem, Executive Director of The Attic Youth Center; mothasistah, an Attic staff member and parent of a transman; Naiymah Sanchez, a trans woman who works for the ACLU of PA; and Dr. Avra Laarakker, Gender Affirming/Plastic & Reconstructive Surgeon with Jefferson Pride Care at Jefferson Einstein Hospital. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

If you're anything like me, you might find the process of what happens to patients when they visit a radiation oncologist somewhat mysterious. During my training, I didn't receive much education about radiation oncology, and I'm not entirely sure what some of the terms mean (hypofractionated means fewer sessions, right?). Well, today's podcast aims to clear up all these uncertainties. We've invited Anish Butala, the Chief of the Palliative Radiotherapy Service at Penn Medicine, and Emily Martin, a palliative care doctor and past president of the Society for Palliative Radiation Oncology (SPRO), to explain everything we should know about radiation oncology. Additionally, Evie Kalmar, who suggested today's topic, will join us as one of our guest hosts. Tune in and we will walk you through the patient's journey from the initial planning visit to the final treatment, discuss common indications like bone and brain metastases, hear about when to consider steroid therapy, and highlight radiation therapy emergencies.

In a medical first, a team at Children's Hospital of Philadelphia and Penn Medicine has successfully treated an infant diagnosed with a rare genetic disorder by using a customized CRISPR gene editing therapy. The work, led by Penn Medicine's Kiran Musunuru and CHOP's Rebecca Ahrens-Nicklas, points to the potential to use bespoke gene editing therapies to treat others with rare genetic diseases for which no available medicines exist. We spoke to P.J. Brooks, deputy director of the Office of Rare Disease Research at the National Institutes of Health's National Center for Advancing Translational Sciences, about the breakthrough treatment, how the researchers were able to move from diagnosis to treatment with great speed, and what it would take to scale such an approach.

New Jersey's primary election is on Tuesday, and the Democratic side of the governor race is packed. KYW's South Jersey Reporter Mike Dougherty looks at the candidates on both sides. Philadelphia City Council and Mayor Cherelle Parker agreed on a $6.8 billion budget. City Hall Bureau Chief Pat Loeb tells us what was approved. Plus, we have updates on a SEPTA line closing, Penn Medicine ending gender-affirming surgeries for people under 19, a bill targeting AI deepfakes, and local students gaining national praise. 00:00 Intro 02:00 The NJ governor race is anybody's game 07:01 What's in Philadelphia's new budget? 13:26 SEPTA's new GM, and Chestnut Hill East Line closes for the summer 19:04 The fight over gender-affirming care for youth 24:59 PA bill addresses AI deepfakes, despite Trump bill to prohibit state AI laws 31:08 Philadelphia students honored in C-SPAN's StudentCam competition Listen to The Week in Philly on KYW Newsradio every Saturday at 5am and 3pm, and Sunday at 3pm. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

The Rich Zeoli Show- Hour 4: 6:05pm- On Thursday, the Trump Administration threatened to withhold federal funding from several sanctuary cities—including Philadelphia, New York City, Los Angeles, and Chicago—if they don't comply with federal law enforcement authorities seeking to crackdown on illegal immigration and the deportation of dangerous migrants residing in the country unlawfully. 6:15pm- While appearing on CNN, White House Deputy Chief of Staff Stephen Miller absolutely destroyed host Pamela Brown when she attempted to downplay border security and the deportation of potentially dangerous migrants who entered the U.S. unlawfully. 6:30pm- Friday marked Elon Musk's last day leading the Department of Government Efficiency (DOGE). President Donald Trump praised Musk's work, highlighting several instances of federal waste that were discovered under his leadership: $101 million for DEI contracts at the Department of Education, $59 million for illegal alien hotel rooms in New York City, $45 million for DEI scholarships in Burma, $42 million for social and behavioral change in Uganda, $20 million for Arab Sesame Street, and $8 million for making mice transgender. As a thank you, Trump presented Musk with a golden key to the White House. 6:40pm- Dr. Stanley Goldfarb—Chairman of Do No Harm & a Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania—joins The Rich Zeoli Show to discuss Penn Medicine's decision to stop performing sex-change surgeries on children. They will, however, continue to prescribe irreversible puberty blockers for children.

1 - Dom kicks off hour 2 with California's updated stance on a trans athlete competing in the women's state high school track meet. How are they going to divvy up the medals if this athlete places above the other competitors? What kind of message does this send to the rest of the field and athletes everywhere? 110 - Your calls. 120 - What is to be done about motorized bicycles and scooters after a child in Williambsurg was decked by a bike and hospitalized? Why don't they follow the rules of the road like cars? Why must pedestrians and motorists constantly battle with them? 130 - Should the Phillies retaliate against the Braves' Spencer Strider for plunking Bryce Harper? The debate ensues. 140 - Some breaking news regarding Penn Medicine! No more gender affirming care. Will CHOP follow suit? Your calls. 150 - Mikie Sherrill doesn't need a 20 million dollar to know what people need, because she “listens”. Will this be a good campaign strategy? Does Mayor Pete think porn will win male voters back? 155 - Is Harvard grossly miscalculating where they stand?

12 - What files should the FBI release first? The listeners speak out in Dom's latest poll. 1205 - Is the Epstein files bigger than the January 6th file? Is Dan Bongino telling the truth about it? Henry doesn't think so. 1215 - Side - good person who did a bad thing 1220 - More on the FBI and the cases that have great public interest. Is Kash Patel as buttoned up as Bongino is on this issue? 1230 - Dom continues on the validity of what Bongino and Patel are saying. 1235 - Whitemarsh resident Christine Balster joins us to celebrate the township reinstating their 4th of July parade. Which township leaders did not show up to their meeting last night, and does this suggest impropriety from them after all this? Why would the town not want to celebrate its own Revolutionary War heritage? 1240 - Your calls. 1250 - Finishing the hour with conspiracy… about mail-in voting! Your calls. 1 - Dom kicks off hour 2 with California's updated stance on a trans athlete competing in the women's state high school track meet. How are they going to divvy up the medals if this athlete places above the other competitors? What kind of message does this send to the rest of the field and athletes everywhere? 110 - Your calls. 120 - What is to be done about motorized bicycles and scooters after a child in Williambsurg was decked by a bike and hospitalized? Why don't they follow the rules of the road like cars? Why must pedestrians and motorists constantly battle with them? 130 - Should the Phillies retaliate against the Braves' Spencer Strider for plunking Bryce Harper? The debate ensues. 140 - Some breaking news regarding Penn Medicine! No more gender affirming care. Will CHOP follow suit? Your calls. 150 - Mikie Sherrill doesn't need a 20 million dollar to know what people need, because she “listens”. Will this be a good campaign strategy? Does Mayor Pete think porn will win male voters back? 155 - Is Harvard grossly miscalculating where they stand? 2 - Karoline Leavitt let the nation know where the Trump administration stands on the trade deficit. Did she sprint to the podium? Does Jasmine Crockett really think Trump would arrest her? 210 - We play a clip of a Sheriff confronting and arresting a man who threatened his life. The kicker? He's a Florida officer who went all the way out to Walla Walla, Washington to nab him! Then by surprise, Sheriff Mike Chitwood quickly joins us to give us the story. How did this whole ordeal start? How did Mike become a target? What steps can be taken to combat this online behavior? What is their local department doing differently from the rest? 225 - Dom thanks the listeners for rising up to save the Whitemarsh Township 4th of July parade. Your calls. 230 - Dom's Money Melody! 240 - Riley Gaines challenges Keith Olbermann to a race. Will he accept? 250 - The Lightning Round!

This episode features Alicia Gresham, Chief Medical Officer and Chief Physician at Penn Medicine. Alicia shares insights into the organization's strategic planning process, including how frontline team members are engaged to help identify new market opportunities. She discusses the evolving challenges in today's healthcare landscape, the ongoing shift toward outpatient care, and the implementation of employee education programs that support long-term transformation at Penn.

Depression, anxiety, and apathy are common symptoms that are often overlooked in people with Parkinson's disease (PD). Nearly half of those living with PD are likely to experience depression or anxiety at some point, but these non-motor symptoms often go unrecognized and undertreated. Because their signs can overlap and mimic one another, it can be challenging to pinpoint exactly what someone is going through. Depression is known for feelings of persistent sadness or hopelessness. Anxiety might look like constant worry, excessive nervousness, or getting upset easily. Apathy, which is sometimes mistaken for depression, is the lack of motivation or interest to do things you used to enjoy. These symptoms can greatly impact your quality of life and worsen other PD symptoms.  In this episode, we speak with Lauren Zelouf, MSW, LCSW from Penn Medicine's Parkinson's Disease & Movement Disorders Center, a Parkinson's Foundation Center of Excellence. She shares how to distinguish among these different symptoms, emphasizes the importance of recognizing the signs, and offers coping strategies for managing symptoms and seeking support. Follow and rate us on your favorite podcast platform to be notified when there's a new episode! Let us know what other topics you would like us to cover by visiting parkinson.org/feedback.

Tackling the labor shortage in science and medicine requires valuing healthcare as a noble profession and using technology to streamline training. In this episode, Kevin Mahoney, CEO of the University of Pennsylvania Health System, discusses the challenges of talent shortages amid a retiring baby boomer generation and a smaller incoming workforce, emphasizing the need for technology to fill the gap. He shares Penn Medicine's innovative initiatives, including flash radiation for cancer treatment and a startup providing maternal support, highlighting their commitment to both technological advancements and human connections. Kevin touches on the need to repair broken systems by speaking to the patients and fixing the issues, refocusing on clinical outcomes, and reimagining the delivery of care. He also underscores that embracing change management with intentionality is crucial for healthcare organizations. Tune in and learn how one of the nation's leading health systems is embracing bold strategies to improve healthcare delivery and workforce development! Resources: Connect with and follow Kevin Mahoney on LinkedIn. Discover more about Penn Medicine's University of Pennsylvania Health System on their LinkedIn and website.

"Weight Loss Revolution: The Truth About GLP-1 Medications" hosted by Kathy Romano Last week, we heard the powerful personal stories of patients who've experienced these medications firsthand – their triumphs, struggles, and everything in between. Now we turn to the medical experts to understand the broader implications of these transformative medications. Three distinguished physicians each bring a unique perspective to the conversation: Dr. Anastassia Amaro, an Obesity Medicine doctor at Penn Medicine and director of Penn Metabolic Medicine; Dr. Rashna Staid, who brings over 25 years of experience in functional and integrative medicine; and Dr. Renee Anderson, a gynecologist specializing in how these medications interact with women's health during perimenopause and menopause. From the physiological mechanisms behind weight loss to concerns about long-term effects, we'll explore the medical realities that go beyond personal experience. Whether you're considering these medications yourself or simply want to understand what's driving this weight loss revolution, you'll want to hear what our experts have to say. Her Story is hosted by Kathy Romano!

In a conversation with CancerNetwork®, Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS, discussed the key findings from a study she published in JAMA Network Open, which demonstrated that most patients with inflammatory breast cancer do not receive all available types of guideline-concordant care they are eligible for. Additionally, data showed disparities regarding receipt of modality-specific therapy among patients who were Black, Asian, Hispanic, or other racial minority populations. Based on these findings, Fayanju highlighted potential next steps for mitigating these gaps in care for certain patients with breast cancer. These strategies included revising stringent inclusion criteria for clinical trial enrollment, which may disproportionately exclude racial minority populations who have higher rates of diabetes or other medical conditions. Fayanju also emphasized educating clinicians across different oncology specialties to recognize how different populations present with inflammatory breast cancer and better understand the context in which patients receive treatment. “I hope [the study] makes some people angry…Frustration can be a wonderful fuel,” Fayanju stated regarding her research. “[By] recognizing that there isn't as much guideline-concordant care receipt amongst all people as there should be and the hope that's provided when we achieve concordant care, we can mitigate and eliminate racial disparities. I hope [that] will motivate people to think about how we can get more guideline-concordant care to more people and how we can incorporate diverse populations in the development of guidelines for concordant care at the beginning. Then, how can we also develop treatments that achieve efficacious results across diverse populations?” Fayanju is the Helen O. Dickens Presidential Associate Professor, chief in the Division of Breast Surgery at Penn Medicine, surgical director of Rena Rowan Breast Center, director of Health Equity Innovation at Penn Center for Cancer Care Innovation (PC3I), and senior fellow at Leonard Davis Institute of Health Economics (LDI), Perelman School of Medicine at the University of Pennsylvania. Reference Tadros A, Diskin B, Sevilimedu V, et al. Trends in guideline-concordant care for inflammatory breast cancer. JAMA Netw Open. 2025;8(2):e2454506. doi:10.1001/jamanetworkopen.2024.54506

April 9, 2025: Kate Gamble and Sarah Richardson discuss a class action lawsuit filed against Penn Medicine regarding its exclusive contract with Independence Blue Cross. The hosts explore how this exclusivity affects patient choice, healthcare access, and market competition in the Philadelphia region. The conversation highlights the growing national scrutiny of healthcare consolidation and encourages IT leaders to evaluate whether their partnerships and systems enhance or restrict patient choice.X: This Week Health LinkedIn: This Week Health Donate: Alex's Lemonade Stand: Foundation for Childhood Cancer

In this episode, Scott Becker covers seven major healthcare stories, from layoffs at Washington Health System and Penn Medicine to policy changes, hospital consolidations, and leadership updates—including Dr. Mehmet Oz's CMS confirmation progress.

As health systems seek solutions to workforce challenges, AI is emerging as a tool to ease the burden on nurses. At Penn Medicine, AI-driven innovations are being explored to streamline workflows, improve documentation, and reduce clinician burnout. Anna Schoenbaum, DNP, MS, RN, VP of Applications, Digital Health & Predictive Health at Penn Medicine, highlighted the […] Source: Properly Leveraging AI to Empower Nurses and Reduce Burnout Takes Careful Study & Deep Engagement on healthsystemcio.com - healthsystemCIO.com is the sole online-only publication dedicated to exclusively and comprehensively serving the information needs of healthcare CIOs.

About Kevin Mahoney:Kevin B. Mahoney is the Chief Executive Officer of the University of Pennsylvania Health System, a cornerstone of Penn Medicine. Overseeing six hospitals, 13 multispecialty centers, and numerous outpatient facilities across Pennsylvania, Delaware, and New Jersey, he leads efforts to advance patient care, medical education, and research. Since joining Penn Medicine in 1996, Mahoney has held key leadership roles, becoming CEO in 2019. He has spearheaded major initiatives, including the development of the 1.5-million-square-foot Pavilion and the integration of Penn Medicine's electronic health records system. A champion of health equity, he established a partnership with Wharton to invest in businesses addressing social determinants of health. Recognized among the most influential figures in healthcare, Mahoney holds an MBA and doctorate from Temple University.Things You'll Learn:The healthcare field faces a critical talent shortage due to retiring baby boomers and a smaller subsequent generation demanding innovative solutions. Cultural shifts are crucial to attracting talent to science and medicine, emphasizing the nobility of healthcare professions over purely financial incentives.Healthcare organizations must remain agile and adaptable, embracing new regulations and technological advancements while staying focused on what matters most: patient care.Artificial intelligence is a crucial tool for achieving precision medicine, enabling proactive healthcare interventions based on individual patient profiles.By repairing systems and improving clinical outcomes, healthcare systems can find ways to continue improving the landscape.Resources:Connect with and follow Kevin Mahoney on LinkedIn.Discover more about Penn Medicine's University of Pennsylvania Health System on their LinkedIn and website.

Become a mini geriatrician in our new Geriatrics series! Geriatricize your knowledge of caring for older adults with unintentional weight loss! You'll round out your history taking and weight gain plan by harnessing the age-friendly “5Ms”. We're joined by Dr. Eva Szymanski (@eva_szy), expert geriatrician at Penn Medicine. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Rapid fire questions Case Defining Unintentional Weight Loss Applying the Geriatric 5Ms Framework Diagnostic Work-Up Addressing Ageism in Medical Decisions Defining Geriatric Syndromes Weight Loss Treatments Outro Credits Producer: Leah Witt, MD, Rachel Miller, MD, MSEd Writers: Abigail Schmucker, MD, Joseph Young, MD, Margaret Heller, MD, Alyson Michener, MD, Leah Witt, MD Show Notes, Infographic and Cover Art: Leah Witt, MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Molly Heublein, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Eva Szymanski, MD Sponsor: Quince Upgrade your closet this year without the upgraded price tag. Go to Quince.com/curb for 365-day returns, plus free shipping on your order! Sponsor: Freed Visit Freed.ai and use code CURB50 to get $50 off your first month.  Sponsor: Mint Mobile Switch to Mint and new customers can get half off an Unlimited plan until February 2. To get your new wireless plan for just $15 a month, and get the plan shipped to your door for FREE, go to MINTMOBILE.com/curb

Can listening to music assist patients' recovery in the perioperative period? On this episode of HSS Presents, Dr. Stephanie Cheng, an anesthesiologist and director of the Perioperative Integrative Medicine program at HSS, talks with Dr. Veena Graff, an anesthesiologist and pain management specialist at Penn Medicine, about the use of music as medicine. They discuss the evidence on using soothing music as a complementary, nonpharmacologic method—pre-, intra-, or postoperatively—and how to implement it for surgical patients.

In this episode of The Brave Enough Show, Dr. Sasha Shillcutt and Dr. Lindsay Semler discuss:   The difference between Moral Distress versus Moral Injury and what it means to those of us in healthcare  How to process failure in our jobs and our lives  How to speak up even when you don't feel safe to do so.     Quote: “The majority of decisions we make every day in healthcare are ethical, moral decisions. They are the hard ones, and the ones where we must feel we have a voice.” Dr. Lindsay Semler      Guest Bio:  Dr. Lindsay Semler is the Executive Director of Clinical Ethics and Department of Medicine Faculty at Brigham and Women's Hospital, and a Lecturer at Harvard Medical School. She is also the Founder & President of Semler Ethics Consulting, LLC. Her background includes critical care and emergency nursing experience, as well as education, quality improvement, and leadership at UPMC and Penn Medicine. She was also the director of the system-wide Ethics program at INTEGRIS Health. Lindsay obtained her BSN and MSN from the University of Pittsburgh, Doctor of Nursing Practice degree with a focus on moral distress from Johns Hopkins, and the Advanced Training in Healthcare Ethics certificate from the University of Washington. She is certified as a Healthcare Ethics Consultant (HEC-C) and critical care nurse (CCRN). Her bioethical areas of interest focus on organizational and preventive healthcare ethics, addressing moral distress, and teaching future generations of healthcare providers.    Lindsay Semler, DNP, RN, CCRN, HEC-C   Executive Director | Ethics Service, Brigham and Women's Hospital  Co-Chair | Ethics Committee, Brigham and Women's Hospital  Faculty | Department of Medicine, Brigham and Women's Hospital  Lecturer | Harvard Medical School  Member | Center for Bioethics, Harvard Medical School  Founder & President | Semler Ethics Consulting https://semlerethicsconsulting.com           Episode Links:  REVIVE Retreat Brave Ballance   Follow Brave Enough:   WEBSITE | INSTAGRAM | FACEBOOK | TWITTER | LINKEDIN Join The Table, Brave Enough's community. The ONLY professional membership group that meets both the professional and personal needs of high-achieving women.

U.S. Steel plans a rally today in Western Pennsylvania to support its acquisition by Nippon Steel, even as reports suggest President Joe Biden will block the sale. Western Pennsylvania oil and gas company PennEnergy will pay a $2 million penalty, and reduce pollution from its facilities, in a proposed settlement with the Justice Department. Penn Medicine is teaming up with billionaire investor Mark Cuban and his prescription marketplace company. New York City’s police commissioner says the gun found on the suspect in the killing of UnitedHealthcare’s CEO matches shell casings found at the crime scene. Luigi Mangione was arrested in Altoona this week. The Hershey Trust says not so fast to a bid to takeover The Hershey Company. It’s been a productive year for bridge repairs in Central Pennsylvania. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

The search for a woman who is believed to have fallen into a sinkhole in Westmoreland County has become a recovery effort after two treacherous days of digging through mud and rock produced no signs of life. Faculty members and coaches at Commonwealth University's Lock Haven campus plan to hold a "no-confidence" vote early next year on the school's  president.  Gun reformers in Pennsylvania say they will pressure state lawmakers to pass stricter firearms laws. Groups like CeaseFire PA want the state to match a federal ban on machine gun conversion devices. Penn Medicine is launching a new program aimed at preventing gun-related injuries in Philadelphia. Organizers say firearm injuries and deaths are reported every year because of improper storage. A shelter in Lancaster will now be able to assist homeless people with extensive medical needs. A Dauphin County man is in custody after police say he shot a rifle into his home while a woman was inside. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

In part two of our conversation with Dr. Mathias Basner, Professor at Penn Medicine and former head of Flight Physiology at the German Aerospace Center, we explore how sleep affects human performance in various environments - from everyday life to the International Space Station. Learn about groundbreaking research on cognitive performance, discover what astronauts can teach us about adapting to challenging sleep conditions, and hear fascinating insights about the future of sleep science. Whether you're optimizing your own performance or curious about human adaptation, this episode offers compelling insights into the science of sleep and performance. In this episode, you will hear: Optimizing sleep environments, including dark, quiet, and cool bedrooms. Impact of technology and screen time on sleep hygiene and strategies to reduce electronic usage. Sleep challenges astronauts face in space, such as microgravity and the 90-minute day-night cycle. Practical solutions for sleep in noisy or brightly lit areas, including air circulation improvements. Exploration of human adaptation in extreme environments, such as Antarctic stations and potential life on Mars. Resources from this Episode To find out more about Dr. Basner:  https://www.med.upenn.edu/uep/faculty_basner.html  Subscribe for more from Frequency:  https://frequencyspaces.com/subscribe  Find out more about Frequency: https://frequencyspaces.com/  Podcast Disclosure:  https://frequencyspaces.com/podcast-disclosure  Follow and Review: We'd love for you to follow us if you haven't yet. Click that purple '+' in the top right corner of your Apple Podcasts app. We'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts. Simply select “Ratings and Reviews” and “Write a Review” then a quick line with your favorite part of the episode. It only takes a second and it helps spread the word about the podcast. Episode Credits If you like this podcast and are thinking of creating your own, consider talking to my producer, Emerald City Productions. They helped me grow and produce the podcast you are listening to right now. Find out more at https://emeraldcitypro.com Let them know we sent you.

Although a high-profile incident at one of its emergency departments garnered recent headlines, Penn Medicine has earned recognition for how it has prioritized workplace violence initiatives that focus on employee safety and well-being. Lisa Triantos, chair of the workplace violence committee at Penn Presbyterian Medical Center, joins the ENA Podcast to talk about what's working amid a system-wide buy-in to find solutions and reduce incidents.

Listen to this powerful interview with Dr. David Fajgenbaum who has an incredible new memoir, "Chasing My Cure: A Doctor's Race to Turn Hope into Action". David's story is truly unique; it's a tale of learning to live, while dying: a universally relatable story about getting up and fighting back after life knocks you down.A former Georgetown quarterback nicknamed "The Beast," David Fajgenbaum was also a force in medical school, where he was known for his unmatched mental stamina. But things changed dramatically when he began suffering from inexplicable fatigue. In a matter of weeks, his organs were failing and he was read his last rites. Doctors were baffled over a condition they had yet to even diagnose; floating in and out of consciousness, Fajgenbaum prayed for the equivalent of a game day overtime: a second chance.Miraculously, Fajgenbaum survived, but only to endure repeated near-death relapses from what would eventually be identified as a form of Castleman disease—an extremely deadly and rare condition that acts like a cross between cancer and an autoimmune disorder. When he relapsed on the only drug in development and realized that the medical community was unlikely to make progress in time to save his life, Fajgenbaum turned his desperate hope for a cure into concrete action: between hospitalizations he studied his own charts and tested his own blood samples, looking for clues that could unlock a new treatment. With the help of family, friends and mentors, he also reached out to other Castleman disease patients and physicians, and eventually came up with an ambitious plan to crowdsource the most promising research questions and recruit world- class researchers to tackle them; instead of waiting for the scientific stars to align, he proposed to align them himself.More than five years later and now married to his college sweetheart, his hard work has paid off: a treatment that he identified has induced a tentative remission and his novel approach to collaborative scientific inquiry has become a blueprint for advancing rare disease research. His incredible story demonstrates the potency of hope, and what can happen when forces of determination, love, family, faith and serendipity collide.David Fajgenbaum, MD, MBA, MSc is one of the youngest individuals to be appointed to the faculty at Penn Medicine. Co- founder and executive director of the Castleman Disease Collaborative Network (CDCN) and an NIH-funded physician- scientist, he has dedicated his life to discovering new treatments and cures for deadly disorders like Castleman disease, which he was diagnosed with during medical school. He is in the top 1 percent youngest grant awardees of an R01, one of the most competitive and sought-after grants in all of biomedical research. Dr. Fajgenbaum has been recognized on the Forbes 30 Under 30 healthcare list, as a top healthcare leader by Becker's Hospital Review, and one of the youngest people ever elected as a Fellow of the College of Physicians of Philadelphia, the nation's oldest medical society. He was one of three recipients – including Vice President Joe Biden – of a 2016 Atlas Award from the World Affairs Council of Philadelphia. Winner of the RARE Champion of Hope: Science award, Dr. Fajgenbaum has been profiled in a cover story by The New York Times as well as by Reader's Digest, Science, and the Today Show. Dr. Fajgenbaum earned a BS from Georgetown University magna cum laude with honors and distinction, MSc from the University of Oxford, MD from the University of Pennsylvania Medical School, and MBA from The Wharton School. He is a former Division I college quarterback, state-champion weight lifter, and co-founder of anational grief support network.Order "Chasing My Cure" at bookstores nationwide or at http://www.chasingmycure.com/

The American Society of Anesthesiologists (ASA)'s annual general meeting; Anesthesiology 2024. Exclusive cutting edge conversations recorded at the conference with some of the key speakers, guests and delegates. The discussion highlights the growing use of the Impella device in anesthesia and critical care, particularly for high-risk patients with severe heart failure or cardiogenic shock. Presented by Desiree Chappell, Monty Mythen and Mike Grocott with their guest Asad Usman, Anesthesiologist, critical care specialist and physician with Penn Medicine, Pennsylvania.

Show SummaryOn today's episode, we're featuring a conversation with Victoria Ring, the National Alliance for Care at Home's Manager of Veterans Services. In this role, Tori manages the We Honor Veterans program, ensuring hospice and palliative care providers are supported and connected with the resources and tools needed to provide quality care that meets the unique needs of Veterans at end of life. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health.  About Today's GuestsVictoria Ring joined the National Alliance for Care at Home in 2023 and serves as the organization's Manager of Veterans Services. In this role, Victoria manages the We Honor Veterans program, ensuring hospice and palliative care providers are supported and connected with the resources and tools needed to provide quality care that meets the uniqueneeds of Veterans at end of life. Her focus is on fostering community connections, ensuring accessibility, promoting health equity, and advancing person-centered and holistic approaches to care. Victoria's deep rooted personal commitment to improving quality of life for older adults with unique needs is reflected in her daily support of We Honor Veterans.Victoria holds a Master of Social Work from the University of Pennsylvania with a Certificate of Specialization in Geriatric Social Work. Her experience includes graduate internships with Pennsylvania Hospital's inpatient proactive psychiatric service line and at Penn Medicine at Home, across their inpatient, outpatient, and bereavement teams. Victoria's prior experience includes employment as a Housing Case Manager, supporting households experiencing intimate partner violence to secure and sustain safe housing. Victoria has prior experience in facilitating public health education. She also holds a Bachelor of Arts in Psychology from the Catholic University of America.Links Mentioned in this Episode We Honor Veterans Web siteMilitary History ChecklistPsychArmor Resource of the WeekCaring for Veterans Through the End Of Life: Healthcare Providers. In this healthcare provider course, you will gain the skills and knowledge to provide compassionate care to our nation's Veterans as they approach the end of their lives. We will examine the specific needs of Veterans and their families, as well as how a patient's military service can impact end-of-life medical care. You will learn how to provide dignified and respectful care that meets the physical, emotional, and spiritual needs of Veteran patients. By the end of this course, you will be equipped to deliver compassionate and sensitive care to Veterans in their final days. You can see find the resource here:   https://learn.psycharmor.org/courses/caring-for-veterans-through-the-end-of-life-healthcare-providers Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on TwitterPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

Renita Miller (Diversity, Equity, and Inclusion Officer at Wharton) and Doctor Joshua Levine (Chief of Penn Medicine's Neurocritical Care) join the show to discuss why financial wellness and health must go hand-in-hand to build stronger communities ahead of The Wellness Empowerment Project Summit. Hosted on Acast. See acast.com/privacy for more information.

Matthew Van Der Tuyn is a designer and healthcare innovation strategist. Matt is the Senior Director of Design and Strategy at the Center for Health Care Transformation and Innovation at Penn Medicine. The mission at the Center is to serve as a catalyst and accelerator for initiatives that dramatically improve health outcomes, patient and provider experiences, and decrease the cost of care. Matt has had the unique opportunity to help build the Center's design, discipline, and elevate design thinking as a key tool in Penn Medicine's organizational toolbox. Matt's design process balances divergent and creative thinking to push beyond incremental solutions with the rigor of an evidence-based approach. We talk about becoming and being a designer in healthcare and Matt's practice. Listen to learn about: >> The unique challenges of designing and innovating in the healthcare space >> Problem-centric vs solution-centric thinking and action >> The importance of change management in the design process Our Guest Matt is a designer and health care innovation strategist. Matt's design roots are in information, product, and service design. His design practice began with visual arts, information design, and product design for luxury goods before deciding to pivot into design for social impact. With this new focus on using design to solve societal issues, Matt's work expanded into the design of services and co-design as a tool for empowering disadvantaged communities. Matt's guiding principle is that design is a mindset that anyone can leverage, and that the role of the “Designer” is to help others tap into this mindset to imagine new possibilities. In 2012, Matt made a leap into health care when he joined the newly minted Center for Health Care Transformation and Innovation at Penn Medicine (CHTI). The mission of this new center was to serve as a catalyst and accelerator for initiatives that dramatically improve health outcomes, patient and provider experiences, and decrease the cost of care. Entering as the first designer on this new team, Matt has had the unique opportunity to help build CHTI's design discipline and elevate design thinking as a key tool in Penn Medicine's organizational toolbox. Matt's design process balances divergent and creative thinking to push beyond incremental solutions with the rigor of an evidence-based approach. Matt leads with the belief that the foundation of great design, and building a culture of innovation, is empowerment. That the greatest ingredient for innovation in any large service organization is the people on the front lines of service delivery who have the passion, insight, and opportunity to effect change. However, there are not often clear pathways for these staff to gain traction with ideas nor are there efficient ways for leadership to identify and support these frontline champions. Matt believes bridging this gap, through design, between high-level organizational objectives and the frontline staff with the answers, where agency is created for innovation, is the key to unlocking the true potential of an organization. Matt does not see design as a silver bullet, but rather a binder that can align the many, diverse, voices and skills needed for transformative solutions. In addition to design, Matt will quickly point to the various disciplines and individuals across Penn Medicine that he feels create the secret sauce that makes anything possible. From behavioral economists to data scientists, quality and safety experts to hospitality experts, Matt is a firm believer that everyone has something to contribute, if we center ourselves around a shared set of values that prioritize improving the lives of others. Show Highlights [02:02] Matt's love of the fine arts, and why he ended up in graphic design. [02:34] Evolving from graphic design into product design of dinnerware. [03:25] The book that helped change Matt's design path. [04:33] Grad school at the University of Arts in Philadelphia. [05:44] How Matt's grad school project with Penn Medicine led to the creation of the Center he works at today. [09:30] Being problem-centric instead of solution-centric. [12:45] The unique challenges of innovation work in healthcare. [14:26] One of Matt's big “a-ha!” moments. [15:29] An exercise Matt uses to help people move past assumptions and think creatively. [18:31] Looking for the people who really wanted the help. [19:34] Storytelling in Matt's work. [22:28] The need for rigor and evidence when designing for healthcare. [24:42] Matt encourages new designers to find ways to measure the success of their work. [25:44] Getting comfortable with the business and finance side of healthcare. [29:38] The importance of good change management. [30:55] Using behavior design to help people with change. [31:27] Conflict as a natural part of the design process. [35:57] Matt's advice for those wanting to work in healthcare design. [38:32] Books and resources Matt recommends. Links Matthew on LinkedIn Matthew at UPenn MedicinePenn Medicine: Center for Health Care Transformation and InnovationA Global Pandemic Turned Everything Upside Down. What Has Penn Medicine's Innovation Team Learned From That?   Book Recommendations Design Revolution: 100 Products The Empower People, by Emily Pilloton The Presentation of Self in Everyday Life, by Erving Goffman DT 101 EpisodesHealthcare + Systems + Risk + Design with Rob Lister — DT101 E122 A Designer's Journey into Designing for Health and Healthcare with Lorna Ross — DT101 E45 Designing Health Systems + Creating Effective Design Workshops with Sean Molloy — DT101 E44

In this episode of DGTL Voices, host Ed welcomes Kevin Mahoney, CEO of the University of Pennsylvania Health System (Penn Medicine). Together, they explore Penn Medicine's mission, the strategic challenges the organization faces, and its commitment to becoming the most clinician-friendly health system. The conversation delves into how technology is reshaping healthcare delivery, the pivotal role tech leaders play in partnering with CEOs, and Kevin's unique leadership style. He shares valuable insights on the importance of authenticity, empathy, and collaboration in driving success in the healthcare industry.

Episode Title: Last Mile with RxMile Part Two: "RxMile Integrations and Success Stories"   Host: Kunal Vyas, CEO & Co-Founder of RxMile Guests: Adam Moon, Medical Pharmacy Matthew Shellenbarger, Director of Pharmacy Operations, Walberg Family Pharmacies Albert M. Giordano, PharmD, Convenience Pharmacy, Penn Medicine Episode Summary: Welcome back to the "Last Mile with RxMile" series! In this exciting part two, host Kunal Vyas dives deeper into the world of pharmacy innovation with special guests Adam Moon from Medical Pharmacy, Matthew Shellenbarger from Walberg Family Pharmacies, and Albert M. Giordano from Penn Medicine's Convenience Pharmacy. This episode, titled "RxMile Integrations and Success Stories," explores how RxMile's cutting-edge technology is revolutionizing the pharmacy landscape. Key Discussion Points: Integration Experience with RxMile: Our guests share their firsthand experiences integrating RxMile into their pharmacy operations. Learn how RxMile's seamless integration process is transforming the way pharmacies manage logistics and deliver medications to patients. Success Stories and Value-Add: Discover real-life success stories that showcase the impact of RxMile on pharmacy businesses and patient care. From improving delivery efficiency to enhancing patient satisfaction, hear how RxMile is adding value across various pharmacy settings. Future Plans and Innovations: Kunal and the guests discuss what's next for RxMile. Get an insider's look at future plans, upcoming innovations, and how RxMile plans to continue leading the charge in pharmacy delivery solutions. Tune in to hear from these industry leaders as they discuss how RxMile is shaping the future of pharmacy delivery, one successful integration at a time! Learn more right now: https://www.rxmile.com/ Listen now on all podcast platforms and don't forget to subscribe, rate, and leave a review.

In this episode, I was lucky enough to interview Mark Allen, Co-founder and CTO of Cobalt Innovations Inc. Mark grew up in Bluebell, Pennsylvania. He credited his wife's influence for igniting his entrepreneurial spirit. Initially working in tech as a software consultant, Mark eventually co-founded Cobalt during the COVID-19 pandemic. The platform was developed rapidly in response to the urgent mental health needs of healthcare workers, with Penn Medicine as their first client. Cobalt provides healthcare institutions with tools to support their employees' mental health, offering services like one-on-one appointments, group sessions, and self-guided resources.Mark also shared insights into the challenges and rewards of balancing his role at Cobalt with his long-term consulting work at Transmogrify, a company he co-founded with Mark Spence. He emphasized the importance of strong relationships and trust in building Cobalt, particularly in securing their first customer through an established connection. Get inspired by Mark Allen's journey from concept to a thriving health tech platform in this insightful episode of The First Customer!Guest Info:Cobalt Innovations Inc.https://www.cobaltinnovations.orgMark Allen's LinkedInhttps://www.linkedin.com/in/mark-allen-721b751/Connect with Jay on LinkedInhttps://www.linkedin.com/in/jayaigner/The First Customer Youtube Channelhttps://www.youtube.com/@thefirstcustomerpodcastThe First Customer podcast websitehttps://www.firstcustomerpodcast.comFollow The First Customer on LinkedInhttp://www.linkedin.com/company/the-first-customer-podcast/